# Johnson & Johnson

Type: Company

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/johnson-johnson
Canonical HTML page: https://getfinancebrief.com/entity/johnson-johnson

## Timeline

- **2026-03-12**: BofA Target Increase — Bank of America raises price target based on pharmaceutical and MedTech pipeline strength.
- **2026-03-10**: Institutional Rebalancing — Richard Bernstein Advisors and Rathbones Group PLC report reduced holdings in JNJ.
- **2026-03-07**: Fast-Track Approval — FDA approves Tecvayli-Darzalex combination for blood cancer treatment.
- **2026-03-05**: FDA Approval & 12-Month High — JNJ receives FDA approval for multiple myeloma combo and stock hits a yearly peak.
- **2026-02-25**: Institutional Exit Revealed — 13F filings reveal a $170 million divestment by a major institutional fund.
- **2026-01-20**: 120% Gain Milestone — PTGX stock reaches a 120% gain milestone from its 52-week low.
- **2025-11-01**: J&J Partnership Milestone — Johnson & Johnson advances JNJ-2113 into late-stage trials, validating oral peptide tech.
- **2025-06-15**: Phase 3 Data Release — Positive Phase 3 data for rusfertide in polycythemia vera triggers initial stock rally.

## Recent coverage (6 stories)

### IHE vs IXJ: 0.39% vs 0.41% Fees — Which Healthcare ETF Wins?
2026-07-19 06:02:54 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

The iShares U.S. Pharmaceuticals ETF (IHE) and iShares Global Healthcare ETF (IXJ) differ in expense ratios (0.39% vs 0.41%), AUM ($1.4B vs $4.1B), and diversification (56 vs 110 holdings). For finance professionals, the 0.02% fee gap may tip the scales for cost-conscious portfolios, but liquidity and global exposure often justify IXJ's slightly higher expense.
Full story: https://getfinancebrief.com/story/ihe-ixj-healthcare-etf-fee-comparison

### Dividend Kings: Defensive Strategies for a Volatile 2026 Market
2026-03-17 11:43:10 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

As the market enters March 2026, investors are increasingly turning to 'Dividend Kings'—companies with over 50 consecutive years of dividend increases—as a defensive hedge against lingering volatility. This briefing analyzes the top three picks for the month: Procter & Gamble, Johnson & Johnson, and Coca-Cola, highlighting their resilience and compounding potential.
Full story: https://getfinancebrief.com/story/dividend-kings-top-picks-march-2026

### BofA Bullish on Johnson & Johnson as Pipeline Momentum Drives Target Hike
2026-03-12 08:12:14 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Bank of America has raised its price target for Johnson & Johnson, citing robust growth in the company's pharmaceutical and MedTech pipelines. The upgrade follows a series of FDA approvals and a strategic pivot toward high-margin innovative medicine after the Kenvue spinoff.
Full story: https://getfinancebrief.com/story/bofa-raises-jnj-price-target-pipeline-growth

### Legend Biotech and Core Molding Unveil 2025 Results Amid Sector Divergence
2026-03-10 13:51:20 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Legend Biotech and Core Molding Technologies released their full-year 2025 financial results, highlighting a period of strategic expansion and operational resilience. While Legend Biotech continues to scale its CAR-T therapy footprint, Core Molding demonstrated steady performance in the industrial manufacturing sector.
Full story: https://getfinancebrief.com/story/legend-biotech-core-molding-2025-earnings-analysis

### Protagonist Stock Surges 120% as Major Fund Reveals $170 Million Exit
2026-02-25 21:49:49 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Protagonist Therapeutics shares have soared 120% following clinical and regulatory milestones, but a recent $170 million institutional exit is raising questions about the stock's near-term ceiling. The move highlights a growing divergence between retail momentum and institutional profit-taking in the biotech sector.
Full story: https://getfinancebrief.com/story/protagonist-therapeutics-stock-surge-institutional-exit

### Genmab Faces Profit Squeeze as R&D for ADC Pipeline Weighs on 2026 Outlook
2026-02-19 08:27:49 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Genmab A/S reported full-year 2025 revenue of $3.72 billion, missing analyst estimates despite strong growth in its core oncology portfolio. The company is prioritizing long-term growth through its $1.8 billion ProfoundBio acquisition and the global rollout of Epkinly, leading to a temporary contraction in net profit margins.
Full story: https://getfinancebrief.com/story/genmab-q4-2025-earnings-analysis-rd-spending

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.